Back in October, I initiated coverage on 10x Genomics (NASDAQ: TXG ), and I was pretty pessimistic . The balance sheet was on the strong side, but with losses expected to persist through at least 2028, I didn't seeI’m Jason Ditz and I have 20 years of experience in foreign policy research. My work has appeared in Forbes, Toronto Star, Minneapolis Star-Tribune, Providence Journal, Washington Times and the Detroit Free Press, as well as American Conservative Magazine and the Quincy Institute for Responsible S ...